FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL										
	OMB Number:	3235-028									
-	Fatimated average I	hurdon									

37 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person Aquestive Therapeutics, Inc. [AQST] Kendall Keith J Director 10% Owner Officer (give title Other (specify X below) below) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 06/30/2019 **CEO** and President C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) Form filed by One Reporting Person WARREN 07059 NJ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 2A. Deemed 5. Amount of 6. Ownership 7. Nature Execution Date. Transaction Securities Form: Direct of Indirect if any (Month/Day/Year) Code (Instr. 8) (D) or Indirect (I) (Instr. 4) Beneficial Ownership (Month/Day/Year) 5) Beneficially Owned Following Reported (Instr. 4) (A) oı (D) Transaction(s) ٧ Price Code Amount

	06/30/2019		F ⁽²⁾		154	D	\$4.2	646,581	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										

M⁽¹⁾

E(2)

, , , , , , , , , , , , , , , , , , , ,															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		And 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	\$0	06/30/2019		M ⁽¹⁾			329	06/30/2019	(3)	Common Stock	329	\$0	1,320	D	

Explanation of Responses:

Common Stock

Common Stock

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 2. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability.
- 3. There are no expiration dates on RSUs.

Remarks:

/s/ Robert Arnold, as Attorney- 07/02/2019 In-Fact

A

D

329

\$0

** Signature of Reporting Person

Date

(Instr. 3 and 4)

646,735

646 591

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

06/30/2019

06/30/2010

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.